Allogene Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $642.84 Mil.
During the past 12 months, Allogene Therapeutics's average Total Assets Growth Rate was -36.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -21.40% per year.
During the past 5 years, the average Total Assets Growth Rate was -1.60% per year.
During the past 7 years, Allogene Therapeutics's highest 3-Year average Total Assets Growth Rate was 23.60%. The lowest was -21.40%. And the median was 17.60%.
Total Assets is connected with ROA %. Allogene Therapeutics's annualizedROA % for the quarter that ended in Dec. 2023 was -52.69%. Total Assets is also linked to Revenue through Asset Turnover. Allogene Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was -0.00.
Allogene Therapeutics Total Assets Historical Data
The historical data trend for Allogene Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Allogene Therapeutics Annual Data
Trend
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
717.80
1,227.83
1,050.83
821.58
642.84
Allogene Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
821.58
746.87
770.97
712.33
642.84
Allogene Therapeutics Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Allogene Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (NAS:ALLO) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Allogene Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Allogene Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Allogene Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Allogene Therapeutics (Allogene Therapeutics) Business Description
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLO has been successfully added to your 